戈舍瑞林联合比卡鲁胺对晚期前列腺癌患者疗效分析  

The Clinical Effect and the Influence of Goserelin Combined with Bicalutamide for Treatment of Patients with Advanced Prostate Cancer

作　　者：江城 许春 刘焜 陈世伟[1] 卢传辉[2] JIANG Cheng;XU Chun;LIU Kun;CHEN Shiwei;LU Chuanhui(Department of Urology, the 174 Hospital of the Chinese People's Liberation Army, Xiamen, Fujian, 361000, China;Department of Oncology, the First Affiliated Hospital of Xiamen University, Xiamen, Fujian, 361000, China)

机构地区：[1]中国人民解放军第一七四医院泌尿外科,福建厦门361000 [2]厦门大学附属第一医院肿瘤科,福建厦门361000

出　　处：《肿瘤药学》2017年第6期678-682,共5页Anti-Tumor Pharmacy

基　　金：国家自然基金青年科学基金项目(81200800)

摘　　要：目的探讨分析戈舍瑞林联合比卡鲁胺在晚期前列腺癌患者中的临床效果及对生存期的影响。方法选取2011年6月~2013年6月我院收治的晚期前列腺癌患者82例,按照随机分配的原则,分为对照组与研究组。对照组患者进行常规的手术去势治疗,研究组采用戈舍瑞林联合比卡鲁胺进行治疗,观察两组患者的临床疗效、临床症状缓解情况、血清前列腺特异性抗原(PSA)水平、不良反应发生率以及生存期的变化。结果治疗后,研究组患者的临床疗效明显高于对照组(P<0.05),研究组临床症状的缓解情况显著优于对照组(P<0.05);治疗前,两组患者的PSA水平无明显差异(P>0.05),治疗3、6、9、12个月后,与对照组相比,研究组PSA水平明显降低(P<0.05);研究组患者不良反应发生率显著低于对照组(P<0.05);与对照组相比,研究组生存期显著延长(P<0.05)。结论戈舍瑞林联合比卡鲁胺能明显降低晚期前列腺癌患者的PSA水平并提高临床疗效,值得临床推广应用。Objective To explore the clinical effect and influence of the combination of goserelin and bicalutamide for patients with advanced prostate cancer.Methods Eighty-two patients with advanced prostate cancer were selected in our hospital from June2011to June2013.They were divided into control group and research group according to the principle of random assignment.Patients in control group were given routine surgical castration treatment,the patients in research group was given goserelin combined with bicalutamide treatment.The clinical efficacy,clinical symptoms,serum prostate specific antigen(PSA)level,changes in the incidence of adverse reactions and survival of patients were observed between the two groups.Results The clinical efficacy of patients after treatment in the study group was significantly higher than that in the control group(P<0.05),and the clinical symptoms of patients in the research group were significantly better than that in the control group(P<0.05).At the same time,PSA levels of patients before the treatment had no significant difference the two groups(P>0.05).The PSA levels of patients in research group significantly decreased after treatment for3,6,9and12months,as compared with those in control group(P<0.05).The incidence of adverse reaction of patients was lower in the research group than in the control group(P<0.05);The survival period of patients in the study group was significantly improved compared with that in the control group(P<0.05).Conclusion Goserelin combined with bicalutamide for patients with advanced prostate cancer could obviously reduce the level of PSA and improve the clinical efficacy.It is worthy of clinical popularization and application.

关 键 词：戈舍瑞林 比卡鲁胺 晚期前列腺癌 生存期 

分 类 号：R737.25[医药卫生—肿瘤]